The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies
Open accessAbstract
Newly emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are continuously posing high global public health concerns and panic resulting in waves of coronavirus disease 2019 (COVID-19) pandemic. Depending on the extent of genomic variations, mutations and adaptation, few of the variants gain the ability to spread quickly across many countries, acquire higher virulency and ability to cause severe disease, morbidity and mortality. These variants have been implicated in lessening the efficacy of the current COVID-19 vaccines and immunotherapies resulting in break-through viral infections in vaccinated individuals and recovered patients. Altogether, these could hinder the protective herd immunity to be achieved through the ongoing progressive COVID-19 vaccination. Currently, the only variant of interest of SARS-CoV-2 is Omicron that was first identified in South Africa. In this review, we present the overview on the emerging SARS-CoV-2 variants with a special focus on the Omicron variant, its lineages and hybrid variants. We discuss the hypotheses of the origin, genetic change and underlying molecular mechanism behind higher transmissibility and immune escape of Omicron variant. Major concerns related to Omicron including the efficacy of the current available immunotherapeutics and vaccines, transmissibility, disease severity, and mortality are discussed. In the last part, challenges and strategies to counter Omicron variant, its lineages and hybrid variants amid the ongoing COVID-19 pandemic are presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528 · cited 1×
“furin cleavage site, which may affect antibody binding and ACE2 binding [87,88].”
BackgroundEffectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · doi:10.1101/2021.12.14.21267615 · Cited by 2,420
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2022) · Nature · doi:10.1038/s41586-021-04385-3 · Cited by 2,006
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
Choi, B., Choudhary, M. C., Regan, J., Sparks, J. A., Padera, R. F., Qiu, X., Solomon, I. H., Kuo, H.-H., Boucau, J., Bowman, K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2031364 · Cited by 1,246
SARS-CoV-2 evolution during treatment of chronic infection
Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I. A. T. M., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I. U., et al. (2021) · Nature · doi:10.1038/s41586-021-03291-y · Cited by 1,097 · cited 1×
“and 90% after three doses has been reported, indicating the rise of protection due to booster vaccine shots which may be due to restoring and increasing the levels of neutralizing antibodies [70,96].”
BackgroundSARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., Duyvesteyn, H. M. E., Ginn, H. M., Mentzer, A. J., Tuekprakhon, A., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.046 · Cited by 930
Plasma Neutralization of the SARS-CoV-2 Omicron Variant
Schmidt, F., Muecksch, F., Weisblum, Y., Da Silva, J., Bednarski, E., Cho, A., Wang, Z., Gaebler, C., Caskey, M., Nussenzweig, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119641 · Cited by 432 · cited 1×
“The persons previously infected or vaccinated may also provide significant protection against Omicron infection [103-105].”
BackgroundGruell, H., Vanshylla, K., Tober-Lau, P., Hillus, D., Schommers, P., Lehmann, C., Kurth, F., Sander, L. E., & Klein, F. (2022) · Nature Medicine · doi:10.1038/s41591-021-01676-0 · Cited by 410
Where did ‘weird’ Omicron come from?
Kupferschmidt, K. (2021) · Science · doi:10.1126/science.acx9738 · Cited by 154 · cited 2×
“diverged at initial phases from other strains [75,76].”
BackgroundMulti-Organ Involvement in COVID-19: Beyond Pulmonary Manifestations
Thakur, V., Ratho, R. K., Kumar, P., Bhatia, S. K., Bora, I., Mohi, G. K., Saxena, S. K., Devi, M., Yadav, D., & Mehariya, S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030446 · Cited by 147
COVID-19 pandemic and its impacts on the environment: A global perspective
Otolorin, G. R., Oluwatobi, A. I., Olufemi, O. T., Esonu, D. O., Dunka, H. I., Adanu, W. A., Danjuma, F. A., Abiayi, D. C., Adegoke, V. A., Omoniwa, D. O., et al. (2022) · Narra J · doi:10.52225/narra.v2i1.72 · Cited by 15
Cited by
Chatterjee, S., Bhattacharya, M., Nag, S., Dhama, K., & Chakraborty, C. (2023) · Viruses · doi:10.3390/v15010167 · Cited by 313
Self-citation
Metadata
- Authors
- Dhama, K., Nainu, F., Frediansyah, A., Yatoo, M. I., Mohapatra, R. K., Chakraborty, S., Zhou, H., Islam, M. R., Mamada, S. S., Kusuma, H. I., Rabaan, A. A., Alhumaid, S., Mutair, A. A., Iqhrammullah, M., Al-Tawfiq, J. A., Mohaini, M. A., Alsalman, A. J., Tuli, H. S., Chakraborty, C., & Harapan, H.
- Venue
- Journal of Infection and Public Health
- Publisher
- Elsevier BV
- Published
- 2023-01
- Volume
- 16
- Issue
- 1
- Pages
- 4-14
- ISSN
- 1876-0341 (ISSN-L)
- OpenAlex
- W4309567317
- Cited by
- 246
- References
- 11
- FWCI
- 26.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.